Israel's Immune Pharma waves the white flag after failing to secure deals for inflammation drug
An eosinophil regulating drug that’s traveled down a winding path to the clinic is once again set to switch hands.
Immune Pharma, which first in-licensed bertilimumab for immunologic and inflammatory diseases in 2011, has filed for Chapter 11 bankruptcy via its US office in New Jersey. Tony Fiorino, former CEO of BrainStorm Cell Therapeutics, has been leading the Israeli biotech ad interim since last August.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.